CLOs on the Move

Armetheon

www.armetheon.com

 
Armetheon, Inc. is a privately held San Francisco Bay area-based biopharmaceutical company with late-stage clinical drug candidates in development for cardiovascular diseases. The company was founded in 2011 by experienced biotech entrepreneurs and drug developers. Armetheon’s two late-stage small molecule drug candidates are for use in the areas of oral anti-coagulation and anti-arrhythmia for atrial fibrillation. The company was founded with the idea that drug innovations can happen by building on the success of proven medications. We create solutions that are within the same class of medication and that utilize the same mechanism of action as existing therapies. This development approach has the ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.armetheon.com
  • 3375 Scott Blvd Suite 306
    Santa Clara, CA USA 95054
  • Phone: 650.646.3898

Executives

Name Title Contact Details

Similar Companies

Zeltiq

Founded in 2005, ZELTIQ is a global medical technology company that developed its patented, non-invasive, and clinically proven CoolSculpting Procedure to selectively reduce exercise-resistant fat bulges.

Abiomed

Abiomed is a manufacturer of medical implant devices, including the AbioCor artificial heart and Impella. It is headquartered in Danvers, Massachusetts and has an additional office in Aachen, Germany. It has 500 employees.

B C Scientific Inc

B C Scientific Inc is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Invivo Corporation

Invivo Corporation is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

StimGuard

StimGuard is a privately held medical device company engaged in the development, manufacture, and pre-commercialization of wirelessly powered, microtechnology neurostimulators, providing patients with a convenient, safe, minimally invasive, and highly cost-effective urological solution that is easily incorporated into their daily lives. StimGuard`s goal is to evolve its patented, cutting-edge platform into the default for neuromodulation, increasing the accessibility for patients worldwide while lowering the economic impact of urology care management.